Glad the FDA doesn't listen to rational less posters like you. Half the patients dropped out the study? Liar comes to mind.
The stock doesn't trade rationally on fundamentals. One day just because Meg what's her face on Fast Money raved about the company the stock ran as high as $134.94. A day later $12 lower?!!! It's not the company I have a problem with. This stock moves because traders are flipping it. Not good.
if anything. Emotional promotion gives way to scientific facts which the FDA bases its decision. Trying to sell this drug will be almost impossible. Half the patients dropped out of the study.
Out of curiosity why did you buy this stock? What motivated the purchase? What information did you base your decision on and how did that information change? Why do you think it is now a pos versus your opinion when you bought it? I ask with the utmost sincerity...just trying to figure out you thought process.
Cashbar1, These swings in price are typical and usual for Vertex,sometimes much more than whats going on now. I'd say the best way to handle it is to decide if you're willing to go through the roller coaster swings betting on approval of this combo, or not. These dips don't mean too much if you look at it like that. The sky isnt falling, and manipulation is usual throughout the market. Lighten up dude. I'm brtting Vertex will make much more money for me than it already has. I've been in since VX-950 was entering into trials.
Sentiment: Strong Buy
This idiot believes by selling his 50 shares will move the market. For months he has been torturing us as if he controls the markets.
Sentiment: Strong Buy
Vertex should get Orkambi approval by Monday or sooner, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said he is confident that the FDA will approve Vertex's Orkambi in homozygous F508del cystic fibrosis by its PDUFA date of July 5, meaning a decision should come by either late Thursday or by Monday morning, due to the holiday. Pricing will be key, Tenthoff noted, adding that he expects it to be in-line with Kalydeco's $311,000, except with steeper gross-to-net discounts. Tenthoff expects Vertex to retain its dominance of CF therapy and keeps his Overweight rating and $146 target on its shares, which closed down $4.84 near $122 yesterday.
I think your contact may have been over simplifying the law for you. The law (you can read at 126 Stat. 1121) does not required the FDA to review in any time period, but to establish regulations to expedite. The FDA per its regs “has committed to a goal to review and act on 90 percent of the applications that have been granted priority review status no later than 6 months after the filing date.” 78 Fed.Reg. 54656. And we know from Kalydeco’s expansion the FDA missed its action date. Plus, think about it: What’s going to happen if the FDA doesn’t meet this deadline? Let’s see: emails deleted. Private servers established. All in violation of the law and what’s that? Oh, I hear crickets chipping.
That said, I have every expectation it will be approved by Friday, but don’t want any Cfers/family to panic if it isn’t. Friday isn’t a “real” deadline, like they have in the private world, or when it’s the IRS expecting you to file your taxes on time.
PS If it isn't approved by Friday the stock will drop I bet 10-20% and if I were a gambler instead of a desperate mom I'd load up the on a margin account!